Clinical trials: Human Influenza
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This is a randomized clinical trial designed to evaluate the safety/efficacy of two dosing regimens of oral nitazoxanide compared to placebo in the treatment of acute uncomplicated influenza in adults and adolescents.
- Trial name
- NCT01227421
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 624 people
- Sponsor
- Romark Laboratories L.C.
Influenza
To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 to 65 years with acute uncomplicated influenza virus infection
- Trial name
- NCT05474755
- Testing
- GP681 40mg
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza
Rapid Diagnostic Test for Influenza
The primary objective of this study is to evaluate the performance of the MSD® Influenza Test in detecting influenza A and influenza B in subjects presenting with influenza-like-illness (ILI).
- Trial name
- NCT01089816
- Testing
- Local/Regional Public Health Notification
- Where
- 4 sites in Vietnam
- Volunteers
- 569 people
- Sponsor
- Meso Scale Diagnostics, LLC.
Avian Influenza, Bird Flu
Safety Study of an Oral Vaccine to Prevent Avian Influenza
The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.
- Trial name
- H5N1 (NCT01335347)
- Testing
- ND1.1
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (<) 13 years of age, with confirmed…
- Trial name
- NCT01715909
- Testing
- Oseltamivir
- Where
- 50 sites in United States, Belgium and 13 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Influenza
A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.
To evaluate the safety of administering 1 or 2 doses of the quadrivalent influenza virus split vaccine (MDCK cells) (0.5ml/dose) in individuals aged 6 months and above.
- Trial name
- NCT06342349
- Testing
- Quadrivalent influenza virus split vaccine (MDCK cells), Quadrivalent influenza virus split vaccine (Chicken embryo), Phosphate buffer solution
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza Prophylaxis
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01863849
- Testing
- Vaccination with Fluval AB suspension for injection
- Where
- 3 sites in Hungary
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025).
- Trial name
- ANCHOR (NCT07159763)
- Testing
- MK-1406
- Where
- 185 sites in United States, Argentina and 4 more
- Volunteers
- 10,000 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Influenza
Ellume·Lab Flu A+B Test and the Ellume Home Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction
The primary purpose of the study is to validate the sensitivity and specificity of the Ellume Home Flu Test and the ellume.lab Flu A+B Test in detecting influenza A and influenza B as compared to reverse transcriptase polymerase…
- Trial name
- NCT03595358
- Testing
- Ellume Home Flu Test, ellume.lab Flu A+B Test, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Ellume Pty Ltd
Clinically Symptomatic Respiratory Illness
Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly
The purpose of this study is to determine if RTB101 prevents illness associated with respiratory tract infections in people ≥65 years of age.
- Trial name
- NCT04139915
- Testing
- Dactolisib
- Sponsor
- Restorbio Inc.
Influenza
Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age
A multi-center, open-label, escalating dose-ranging study to assess the safety, reactogenicity, and immunogenicity of four different VAX125 vaccine doses; 0.5 µg, 1.0 µg, 2.0 µg, or 3.0 µg, delivered i.m.
- Trial name
- NCT00966238
- Testing
- VAX125
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza
Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958
The purpose of this study is to test the safety and tolerability of an investigational multi-dose inhaled flu medication, CS-8958. Study participants will include 16 males and females, aged 18-55 years of age, inclusive.
- Trial name
- NCT00995826
- Testing
- CS-8958
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
H7N9 Subtype of Influenza A Virus
Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection
The purpose of this program is to provide pre-approval access to pimodivir for the treatment of a patient(s) with H7N9 influenza A infection.
- Trial name
- NCT03834376
- Testing
- Pimodivir
- Sponsor
- Janssen Research & Development, LLC
Influenza
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
The primary objectives of the study are: To describe the safety profile of the different quadrivalent recombinant influenza vaccine (RIV) formulations.
- Trial name
- FBP00001 (NCT04144179)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, Influenza
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
- Trial name
- NCT06694389
- Testing
- mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 2,457 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
This study is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.
- Trial name
- NCT00192127
- Testing
- FluMist
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly…
- Trial name
- NCT02369341
- Testing
- Fluarix Tetra
- Where
- 2 sites in Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine
The aim of this study is to investigate the long-term immunogenicity and safety of the inactivated split-virion vaccine after one immunization.
- Trial name
- NCT01336166
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted H1N1 vaccine of 30 μg, split-virion, non-adjuvanted H1N1 vaccine of 45 μg
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Safety Issues
Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu
This is a single-site, randomized, double-blind, placebo-controlled study of Uniflu in fifty four (54) volunteers 18-60 years of age with a dose escalation.
- Trial name
- NCT03789539
- Testing
- LD Universal Influenza Vaccine Uniflu, HD Universal Influenza Vaccine Uniflu
- Where
- Russia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Pharma Limited Liability Company